Trimetazidine Modified Release in???the???Treatment of Stable Angina

Abstract

To assess the clinical efficacy, safety and effects on quality of life of trimetazidine modified release (MR) in patients with stable angina. This large, open-label, uncontrolled study was conducted in 906 patients with stable angina in the Russian Federation. Patients were treated for 8 weeks with trimetazidine MR (35mg tablet, twice a day) in addition to their conventional therapy. Overall 846 patients (516 men and 330 women) aged 58.7 ±9 years completed the study. During the 8-week treatment period the number of angina attacks per week decreased continuously and significantly from 11.2 ±0.4 to 3.6 ±0.2 (p < 0.0001). Concurrently, the number of short-acting nitrate tablets taken per week decreased from 11.9 ±0.8 to 3.4 ±0.2 (p < 0.0001). Patients’ quality of life, assessed on the Seattle Angina Questionnaire, showed a significant improvement (p < 0.0001) for all five items evaluated: physical limitation increased from 50.7 ±0.7 to 61.0 ±0.6, angina stability improved from 57.6 ±0.9 to 92.5 ±0.7, angina frequency extended from 33.3 ±0.7 to 55.6 ±0.8, treatment satisfaction increased from 62.3 ±0.7 to 77.4 ±0.5, and disease perception improved from 36.7 ±0.6 to 55.5 ±0.7. Adverse events were reported in 2.4% of patients (22/906) during the 8 weeks of treatment. No serious adverse events were reported. The results of this study suggest an improvement in clinical efficacy and in quality of life and a good tolerance of trimetazidine MR administered at a dose of 35mg twice a day for 8 weeks in patients with stable angina.